Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
When people living with HIV are admitted to a hospital, they may not be able to bring their medications with them, and could be prescribed new medication by a doctor who doesn't understand their complete medical history.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
A cellphone attachment that detects HIV RNA; HIV-2 does indeed often progress to AIDS; CD4 count declines and incident hepatitis C coinfection; the global demographics of non-Hodgkin lymphoma.
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
A study of people with HIV and hepatitis C co-infection finds that limited access to food is associated with higher levels of HIV in the blood and 10% fewer CD4+ immune cells.
Cost issues are a major potential barrier toward effective HIV treatment, and many people with HIV experience financial stress. Sean Hosien of CATIE outlines a study that explores the impacts of this stress among people with HIV in Australia.
Here's a quick sampling of some of the more noteworthy HIV-related posters presented at a major research conference last week. Topics covered include a surprisingly high frequency of people quitting Atripla due to side effects; the decline of multidr...